[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20032233L - Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer - Google Patents

Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer

Info

Publication number
NO20032233L
NO20032233L NO20032233A NO20032233A NO20032233L NO 20032233 L NO20032233 L NO 20032233L NO 20032233 A NO20032233 A NO 20032233A NO 20032233 A NO20032233 A NO 20032233A NO 20032233 L NO20032233 L NO 20032233L
Authority
NO
Norway
Prior art keywords
renin inhibitor
cardiovascular diseases
synergistic compounds
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20032233A
Other languages
English (en)
Other versions
NO20032233D0 (no
NO334002B1 (no
Inventor
William Hewitt
Daniel Lucius Vasella
Randy Lee Webb
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032233(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of NO20032233D0 publication Critical patent/NO20032233D0/no
Publication of NO20032233L publication Critical patent/NO20032233L/no
Publication of NO334002B1 publication Critical patent/NO334002B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
NO20032233A 2000-11-17 2003-05-16 Farmasøytisk sammensetning som omfatter renininhibitoren aliskiren, og minst ett ytterligere terapeutisk middel, anvendelse derav, samt kitt NO334002B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
PCT/EP2001/013241 WO2002040007A1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Publications (3)

Publication Number Publication Date
NO20032233D0 NO20032233D0 (no) 2003-05-16
NO20032233L true NO20032233L (no) 2003-05-16
NO334002B1 NO334002B1 (no) 2013-11-11

Family

ID=9903412

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20032233A NO334002B1 (no) 2000-11-17 2003-05-16 Farmasøytisk sammensetning som omfatter renininhibitoren aliskiren, og minst ett ytterligere terapeutisk middel, anvendelse derav, samt kitt
NO2013019C NO2013019I1 (no) 2000-11-17 2013-12-17 Kombinasjon omfattende aliskiren, som den frie basen eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2013019C NO2013019I1 (no) 2000-11-17 2013-12-17 Kombinasjon omfattende aliskiren, som den frie basen eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.

Country Status (32)

Country Link
US (4) US8168616B1 (no)
EP (7) EP2305231A1 (no)
JP (6) JP2004513920A (no)
KR (6) KR20100114904A (no)
CN (4) CN101264073A (no)
AT (2) ATE317692T1 (no)
AU (2) AU2368002A (no)
BR (1) BR0115411A (no)
CA (2) CA2428647A1 (no)
CY (5) CY1105603T1 (no)
CZ (2) CZ299749B6 (no)
DE (3) DE60117295T2 (no)
DK (3) DK1341533T3 (no)
EC (1) ECSP034603A (no)
ES (4) ES2429292T3 (no)
GB (1) GB0028151D0 (no)
HK (3) HK1089356A1 (no)
HU (2) HU230882B1 (no)
IL (3) IL155707A (no)
LU (2) LU91563I2 (no)
MX (1) MXPA03004358A (no)
NL (2) NL300385I1 (no)
NO (2) NO334002B1 (no)
NZ (6) NZ525795A (no)
PL (3) PL400914A1 (no)
PT (3) PT1602370E (no)
RU (2) RU2310443C2 (no)
SG (1) SG135969A1 (no)
SI (3) SI1602370T1 (no)
SK (1) SK287881B6 (no)
WO (1) WO2002040007A1 (no)
ZA (1) ZA200303497B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
SI1507558T1 (sl) 2002-05-17 2011-12-30 Novartis Pharma Ag Farmacevtski sestavek, ki obsega reninski inhibitor, blokator kalcijevega kanala in diuretik
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
ATE344026T1 (de) * 2002-06-28 2006-11-15 Speedel Pharma Ag Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
CA2600973C (en) 2003-11-26 2012-08-07 Novartis Ag .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US7786307B2 (en) 2004-01-23 2010-08-31 Novartis Ag Amino alcohol derivatives and their activity as renin inhibitors
CA2553836A1 (en) * 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their use as renin inhibitors
PT1735270E (pt) * 2004-01-23 2010-08-27 Novartis Ag Diamino-álcoois e sua utilização como inibidores da renina
PE20060075A1 (es) * 2004-03-17 2006-03-20 Novartis Ag Composiciones farmaceuticas de alisciren
NZ586285A (en) * 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
CA2560195A1 (en) * 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
RU2407523C2 (ru) * 2004-10-08 2010-12-27 Новартис Аг Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
CA2605771A1 (en) * 2005-04-27 2006-11-02 Novartis Ag Methods of treating atherosclerosis
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
ES2303198T3 (es) * 2005-09-28 2008-08-01 Teva Pharmaceutical Industries Ltd. Combinaciones estables de besilato de amlodipina e hidrocloruro de benazeprilo.
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
JP2009514961A (ja) * 2005-11-08 2009-04-09 ノバルティス アクチエンゲゼルシャフト アンギオテンシンｉｉ受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
MX2008011842A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica.
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
BRPI0721167A2 (pt) * 2006-12-15 2014-03-18 Novartis Ag Inibidores de renina para prevenção e tratamento de hipertensão em pacientes obesos.
EP2120899A1 (en) * 2007-02-14 2009-11-25 Gilead Colorado, Inc. Antihypertensive drug combination
CN101808631A (zh) * 2007-09-28 2010-08-18 诺瓦提斯公司 阿利吉仑和缬沙坦的盖仑制剂
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
CN102014881A (zh) 2008-02-22 2011-04-13 韩兀生物制药株式会社 药物制剂
US20110111022A1 (en) 2008-04-10 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical formulation
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
CN102065847A (zh) 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
CN102348452A (zh) 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2704706A1 (en) 2011-05-06 2014-03-12 Artskin D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
CN109568253B (zh) * 2012-05-18 2022-04-26 罗达制药有限公司 液体制剂
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
EP3174530B1 (de) 2014-07-30 2018-08-29 Merck Patent GmbH Direkt verpressbare polyvinylalkohole
AU2017350484B2 (en) * 2016-10-27 2021-12-02 Damian Pharma Ag Aldosterone synthase inhibitor

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
DK0955294T3 (da) 1989-06-14 2004-02-02 Smithkline Beecham Corp Imidazolylalkensyre
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
KR970005839B1 (ko) 1990-05-11 1997-04-21 화이자 인코포레이티드 상승 치료효과를 얻기 위한 조성물 및 방법
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
JPH06500111A (ja) * 1990-08-15 1994-01-06 アボツト・ラボラトリーズ レニン阻害剤
CA2098176C (en) * 1990-12-14 2006-12-12 Joseph Weinstock Angiotensin ii receptor blocking compositions
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
WO1992013564A1 (en) 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (no) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
AP573A (en) 1993-04-27 1997-01-30 Smithkline Beecham Corp Endothelin receptor antagonists.
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
ATE198551T1 (de) * 1993-07-15 2001-01-15 Hoffmann La Roche Pharmazeutische kombination, die einen hemmer des renin-angiotensin-systems und einen endothelin- antagonisten enthält
ATE199151T1 (de) 1993-08-18 2001-02-15 Banyu Pharma Co Ltd Kondensierte heteroaromatische cyclopentenderivate mit endothelin- antagonistischer aktivität
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
AU711832B2 (en) 1994-08-19 1999-10-21 Abbvie Bahamas Ltd. Endothelin antagonists
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (no) 1994-12-20 1997-08-21 Hoffmann La Roche
AU706940B2 (en) 1995-01-27 1999-07-01 Rhone-Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
EP0882719B1 (en) 1995-12-20 2001-05-16 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
AU1319697A (en) 1996-01-23 1997-08-20 Shionogi & Co., Ltd. Process for producing oleanolic acid analogs by culturing hairy root
ES2241047T3 (es) 1996-04-04 2005-10-16 Banyu Pharmaceutical Co., Ltd. Antagonistas de la endotelina para tratar la insuficiencia cardiaca.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
EP1087775B1 (en) * 1998-06-17 2005-08-17 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
AU763309B2 (en) 1998-07-20 2003-07-17 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CA2368187A1 (en) * 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
EP1227804B1 (en) 1999-11-09 2007-08-22 Pharmacia Corporation Use of eplerenone for treating restenosis
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
SI1507558T1 (sl) * 2002-05-17 2011-12-30 Novartis Pharma Ag Farmacevtski sestavek, ki obsega reninski inhibitor, blokator kalcijevega kanala in diuretik
ATE397147T1 (de) 2002-12-31 2008-06-15 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
US9023894B2 (en) 2015-05-05
DE60117295D1 (de) 2006-04-20
SI1602370T1 (sl) 2008-10-31
SI1341533T1 (sl) 2006-08-31
IL212075A0 (en) 2011-06-30
CY2013045I1 (el) 2015-11-04
CN101264072A (zh) 2008-09-17
IL155707A (en) 2012-02-29
EP1341533A1 (en) 2003-09-10
NO20032233D0 (no) 2003-05-16
US8618174B2 (en) 2013-12-31
US20120016035A1 (en) 2012-01-19
HU230882B1 (hu) 2018-11-29
GB0028151D0 (en) 2001-01-03
JP2013213061A (ja) 2013-10-17
PL400915A1 (pl) 2012-12-17
NL300385I1 (nl) 2009-07-01
KR101008752B1 (ko) 2011-01-14
NZ568764A (en) 2009-11-27
CN100404024C (zh) 2008-07-23
NO2013019I2 (no) 2013-12-17
JP2018030894A (ja) 2018-03-01
HK1059212A1 (en) 2004-06-25
RU2346703C2 (ru) 2009-02-20
ES2429292T3 (es) 2013-11-14
PT1602370E (pt) 2008-09-10
EP1930000A1 (en) 2008-06-11
EP1341533B1 (en) 2006-02-15
EP1602370A2 (en) 2005-12-07
EP1915993A1 (en) 2008-04-30
ES2256335T3 (es) 2006-07-16
CN1474690A (zh) 2004-02-11
CA2763223A1 (en) 2002-05-23
CZ305341B6 (cs) 2015-08-05
BR0115411A (pt) 2004-08-17
CN101091703A (zh) 2007-12-26
US8168616B1 (en) 2012-05-01
RU2006132668A (ru) 2008-03-20
EP1602370B1 (en) 2008-06-04
ATE397445T1 (de) 2008-06-15
PT1341533E (pt) 2006-06-30
IL212075A (en) 2013-08-29
HUP0301841A2 (hu) 2003-09-29
NL301005I2 (nl) 2019-10-29
KR101258365B1 (ko) 2013-04-30
NZ525795A (en) 2005-03-24
EP2305232B1 (en) 2019-07-17
KR20030051753A (ko) 2003-06-25
DK1602370T3 (da) 2008-09-22
IL155707A0 (en) 2003-11-23
DE60134349D1 (de) 2008-07-17
JP6089278B2 (ja) 2017-03-08
SK287881B6 (sk) 2012-02-03
HUP0301841A3 (en) 2010-07-28
EP2305233A1 (en) 2011-04-06
NZ550898A (en) 2008-07-31
LU91563I2 (fr) 2009-07-06
CY1108305T1 (el) 2012-01-25
WO2002040007A1 (en) 2002-05-23
PL227576B1 (pl) 2017-12-29
SI1915993T1 (sl) 2013-10-30
DE60117295T2 (de) 2006-08-17
MXPA03004358A (es) 2003-08-19
SG135969A1 (en) 2007-10-29
EP2305231A1 (en) 2011-04-06
CN101264073A (zh) 2008-09-17
JP2018131465A (ja) 2018-08-23
RU2310443C2 (ru) 2007-11-20
CY2009005I1 (el) 2012-01-25
ES2308347T3 (es) 2008-12-01
EP2305232A1 (en) 2011-04-06
KR20080097488A (ko) 2008-11-05
HU1400409D0 (hu) 2003-09-29
KR20100114904A (ko) 2010-10-26
CZ299749B6 (cs) 2008-11-12
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
US9023893B2 (en) 2015-05-05
NZ537691A (en) 2007-01-26
ZA200303497B (en) 2004-04-28
PL400914A1 (pl) 2012-12-17
ATE317692T1 (de) 2006-03-15
IL217847A0 (en) 2012-03-29
US20120004312A1 (en) 2012-01-05
JP2017019876A (ja) 2017-01-26
JP2009235107A (ja) 2009-10-15
JP2004513920A (ja) 2004-05-13
ES2734523T3 (es) 2019-12-10
EP1602370A3 (en) 2005-12-14
DK1915993T3 (da) 2013-10-14
AU2002223680B2 (en) 2005-04-07
NO2013019I1 (no) 2014-06-02
JP6373931B2 (ja) 2018-08-15
CA2428647A1 (en) 2002-05-23
NZ550897A (en) 2008-03-28
NL301005I1 (no) 2019-09-10
LU92315I2 (fr) 2014-01-27
KR20080011355A (ko) 2008-02-01
DK1341533T3 (da) 2006-05-08
NO334002B1 (no) 2013-11-11
AU2368002A (en) 2002-05-27
ECSP034603A (es) 2003-06-25
US20120010295A1 (en) 2012-01-12
JP6603757B2 (ja) 2019-11-06
HK1089356A1 (en) 2006-12-01
HK1115544A1 (en) 2008-12-05
DE122009000021I1 (de) 2009-08-06
JP6577994B2 (ja) 2019-09-18
CY2013045I2 (el) 2015-11-04
KR20110063596A (ko) 2011-06-10
PL361404A1 (en) 2004-10-04
KR20080096715A (ko) 2008-10-31
EP1915993B1 (en) 2013-07-10
CY1114829T1 (el) 2015-11-04
SK5842003A3 (en) 2003-11-04
CY1105603T1 (el) 2010-07-28
CY2009005I2 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
WO2004112710A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
AU3664401A (en) Platelet adp receptor inhibitors
EP1734041A3 (en) Platelet ADP receptor inhibitors
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
RU2000128859A (ru) Способ защиты печени от ксенобиотиков в эксперименте
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS PHARMA AG, CH

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: RASILEZ HCT; REG. NO/DATE: EU/1/08/491/001-080 20090219

Spc suppl protection certif: 2013019

Filing date: 20131217

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: RASILEZ HCT; REG. NO/DATE: EU/1/08/491/001-080 20090219

Spc suppl protection certif: 2013019

Filing date: 20131217

Extension date: 20231028

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NODEN PHARMACEUTICALS DAC, IE

MM1K Lapsed by not paying the annual fees